Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

April 01, 2020; Volume 373,Issue 1

Behavioral Pharmacology

  • You have access
    Mice with GNAO1 R209H Movement Disorder Variant Display Hyperlocomotion Alleviated by Risperidone
    Casandra L. Larrivee, Huijie Feng, Josiah A. Quinn, Vincent S. Shaw, Jeffrey R. Leipprandt, Elena Y. Demireva, Huirong Xie and Richard R. Neubig
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 24-33; DOI: https://doi.org/10.1124/jpet.119.262733
  • You have access
    Cannabinoid Modulation of Food-Cocaine Choice in Male Rhesus Monkeys
    William S. John, Thomas J. Martin and Michael A. Nader
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 44-50; DOI: https://doi.org/10.1124/jpet.119.263707
  • You have access
    Enhancing KCNQ Channel Activity Improves Neurobehavioral Recovery after Spinal Cord Injury
    Zizhen Wu, Lin Li, Fuhua Xie, Guoying Xu, Danny Dang and Qing Yang
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 72-80; DOI: https://doi.org/10.1124/jpet.119.264010
  • You have access
    NR2A-NMDA Receptor Blockade Reverses the Lack of Morphine Analgesia Without Affecting Chronic Pain Status in a Fibromyalgia-Like Mouse Model
    Hiroyuki Neyama, Naoki Dozono and Hiroshi Ueda
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 103-112; DOI: https://doi.org/10.1124/jpet.119.262642

Cardiovascular

  • Open Access
    DPP4 Inhibition, NPY1-36, PYY1-36, SDF-1α, and a Hypertensive Genetic Background Conspire to Augment Cell Proliferation and Collagen Production: Effects That Are Abolished by Low Concentrations of 2-Methoxyestradiol
    Edwin K. Jackson, Delbert G. Gillespie and Stevan P. Tofovic
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 135-148; DOI: https://doi.org/10.1124/jpet.119.263467

Drug Discovery and Translational Medicine

  • Open Access
    Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats
    Bartlomiej Kalaska, Joanna Miklosz, Kamil Kamiński, Justyna Swieton, Aleksandra Jakimczuk, Shin-Ichi Yusa, Dariusz Pawlak, Maria Nowakowska, Krzysztof Szczubiałka and Andrzej Mogielnicki
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 51-61; DOI: https://doi.org/10.1124/jpet.119.262931
  • You have access
    The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action
    Nina Sonne, Anna Thorsø Larsen, Kim Vietz Andreassen, Morten Asser Karsdal and Kim Henriksen
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 92-102; DOI: https://doi.org/10.1124/jpet.119.263723
  • Open Access
    CDDO-Me Elicits Anti–Breast Cancer Activity by Targeting LRP6 and FZD7 Receptor Complex
    Liang Zhou, Zhongyuan Wang, Shubin Yu, Yanpeng Xiong, Jiaoyang Fan, Yansi Lyu, Zijie Su, Jiaxing Song, Shanshan Liu, Qi Sun and Desheng Lu
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 149-159; DOI: https://doi.org/10.1124/jpet.119.263434

Endocrine and Diabetes

  • You have access
    Oleoylethanolamide Increases Glycogen Synthesis and Inhibits Hepatic Gluconeogenesis via the LKB1/AMPK Pathway in Type 2 Diabetic Model
    Tong Ren, Ang Ma, Rengong Zhuo, Huaying Zhang, Lu Peng, Xin Jin, Enhui Yao and Lichao Yang
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 81-91; DOI: https://doi.org/10.1124/jpet.119.262675

Gastrointestinal, Hepatic, Pulmonary, and Renal

  • You have access
    Leukotriene B4 Receptor Type 2 Accelerates the Healing of Intestinal Lesions by Promoting Epithelial Cell Proliferation
    Yui Matsumoto, Yukiko Matsuya, Kano Nagai, Kikuko Amagase, Kazuko Saeki, Kenjiro Matsumoto, Takehiko Yokomizo and Shinichi Kato
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 1-9; DOI: https://doi.org/10.1124/jpet.119.263145
  • Open Access
    CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome
    Alexander Roberts, Gillian Grafton, Andrew D. Powell, Kristian Brock, Chunlin Chen, Dejian Xie, Jinkun Huang, Shuang Liu, Alison J. Cooper, Catherine A. Brady, Omar Qureshi, Zania Stamataki, David D. Manning, Nicholas A. Moore, Bruce J. Sargent, Peter R. Guzzo and Nicholas M. Barnes
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 122-134; DOI: https://doi.org/10.1124/jpet.119.261008

Metabolism, Transport, and Pharmacogenomics

  • You have access
    Probing the Assembly of HDL Mimetic, Drug Carrying Nanoparticles Using Intrinsic Fluorescence
    Sangram Raut, Ashwini Garud, Bhavani Nagarajan, Nirupama Sabnis, Alan Remaley, Rafal Fudala, Ignacy Gryczynski, Zygmunt Gryczynski, Sergei V. Dzyuba, Julian Borejdo and Andras Lacko
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 113-121; DOI: https://doi.org/10.1124/jpet.119.262899

Neuropharmacology

  • You have access
    Dorsoventral-Specific Effects of Nerve Agent Surrogate Diisopropylfluorophosphate on Synaptic Transmission in the Mouse Hippocampus
    Kyle A. Brown, Nikolay M. Filipov and John J. Wagner
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 10-23; DOI: https://doi.org/10.1124/jpet.119.263053
  • You have access
    Detailed In Vitro Pharmacological Characterization of the Clinically Viable Nociceptin/Orphanin FQ Peptide Receptor Antagonist BTRX-246040
    Federica Ferrari, Sabrina Rizzo, Chiara Ruzza and Girolamo Calo
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 34-43; DOI: https://doi.org/10.1124/jpet.119.262865
  • Open Access
    Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor
    Eric Moore, Mark E. Fraley, Ian M. Bell, Christopher S. Burgey, Rebecca B. White, Chi-Chung Li, Christopher P. Regan, Andrew Danziger, Maria Stranieri Michener, Eric Hostetler, Pradeep Banerjee and Christopher Salvatore
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 160-166; DOI: https://doi.org/10.1124/jpet.119.261065

Toxicology

  • You have access
    Arsenite-Induced Mitochondrial Superoxide Formation: Time and Concentration Requirements for the Effects of the Metalloid on the Endoplasmic Reticulum and Mitochondria
    Andrea Guidarelli, Liana Cerioni, Mara Fiorani, Alessia Catalani and Orazio Cantoni
    Journal of Pharmacology and Experimental Therapeutics April 2020, 373 (1) 62-71; DOI: https://doi.org/10.1124/jpet.119.262469
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics: 373 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 373, Issue 1
1 Apr 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts

Jump to

  • Behavioral Pharmacology
  • Cardiovascular
  • Drug Discovery and Translational Medicine
  • Endocrine and Diabetes
  • Gastrointestinal, Hepatic, Pulmonary, and Renal
  • Metabolism, Transport, and Pharmacogenomics
  • Neuropharmacology
  • Toxicology
  • Most Read
Loading
  • Potential Clinical Uses of CBG
  • Ocular Drug Delivery: Past, Present, and Future
  • Nose-to-Brain Delivery
  • Antipsychotic-VMAT2 Inhibitor Synergy: Schizophrenia Models
  • SEP-363856, a Novel, Non-D2 Psychotropic Agent
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics